Rexious Spinal Fixation System

K173131 · Huvexel Co. , Ltd. · NKB · Dec 8, 2017 · Orthopedic

Device Facts

• Record ID: K173131
• Device Name: Rexious Spinal Fixation System
• Applicant: Huvexel Co. , Ltd.
• Product Code: NKB · Orthopedic
• Decision Date: Dec 8, 2017
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 888.3070
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Rexious Spinal Fixation System is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of the following acute and chronic instabilities or deformities of the thoracic, lumbar, and sacral spine: degenerative disc disease; spondylolisthesis; fracture; dislocation; scoliosis; kyphosis; spinal tumor; and failed previous fusion (pseudarthrosis).

Device Story

Rexious Spinal Fixation System is a top-loading, posterior spinal fixation system comprising pedicle screws, rods, set screws, connectors, and transverse linking mechanisms. Surgeons use these components to construct a spinal implant construct to stabilize and promote spinal fusion. The device is supplied non-sterile for single use. It is intended for use in the thoracic, lumbar, and sacral spine to treat various instabilities or deformities. The system provides mechanical immobilization of spinal segments to facilitate fusion.

Clinical Evidence

Bench testing only. Static and dynamic compression bend tests were performed in accordance with ASTM F1717. No clinical data was provided.

Technological Characteristics

Materials: Titanium or titanium alloy (Ti-6Al-4V ELI) per ASTM F67, F136, F1295; Cobalt-Chromium-Molybdenum (CoCr) per ASTM F1537. System components include pedicle screws, rods, set screws, connectors, and transverse links. Non-sterile, single-use, mechanical fixation system.

Indications for Use

Indicated for skeletally mature patients requiring spinal immobilization/stabilization as an adjunct to fusion for thoracic, lumbar, and sacral spine conditions including degenerative disc disease, spondylolisthesis, fracture, dislocation, scoliosis, kyphosis, spinal tumor, and pseudarthrosis.

Regulatory Classification

Identification

(1) Rigid pedicle screw systems are comprised of multiple components, made from a variety of materials that allow the surgeon to build an implant system to fit the patient's anatomical and physiological requirements. Such a spinal implant assembly consists of a combination of screws, longitudinal members (e.g., plates, rods including dual diameter rods, plate/rod combinations), transverse or cross connectors, and interconnection mechanisms (e.g., rod-to-rod connectors, offset connectors).(2) Semi-rigid systems are defined as systems that contain one or more of the following features (including but not limited to): Non-uniform longitudinal elements, or features that allow more motion or flexibility compared to rigid systems.

Special Controls

*Classification.* (1) Class II (special controls), when intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of the following acute and chronic instabilities or deformities of the thoracic, lumbar, and sacral spine: severe spondylolisthesis (grades 3 and 4) of the L5-S1 vertebra; degenerative spondylolisthesis with objective evidence of neurologic impairment; fracture; dislocation; scoliosis; kyphosis; spinal tumor; and failed previous fusion (pseudarthrosis). These pedicle screw spinal systems must comply with the following special controls:(i) Compliance with material standards; (ii) Compliance with mechanical testing standards; (iii) Compliance with biocompatibility standards; and (iv) Labeling that contains these two statements in addition to other appropriate labeling information: “Warning: The safety and effectiveness of pedicle screw spinal systems have been established only for spinal conditions with significant mechanical instability or deformity requiring fusion with instrumentation. These conditions are significant mechanical instability or deformity of the thoracic, lumbar, and sacral spine secondary to severe spondylolisthesis (grades 3 and 4) of the L5-S1 vertebra, degenerative spondylolisthesis with objective evidence of neurologic impairment, fracture, dislocation, scoliosis, kyphosis, spinal tumor, and failed previous fusion (pseudarthrosis). The safety and effectiveness of these devices for any other conditions are unknown.” “Precaution: The implantation of pedicle screw spinal systems should be performed only by experienced spinal surgeons with specific training in the use of this pedicle screw spinal system because this is a technically demanding procedure presenting a risk of serious injury to the patient.” (2) Class II (special controls), when a rigid pedicle screw system is intended to provide immobilization and stabilization of spinal segments in the thoracic, lumbar, and sacral spine as an adjunct to fusion in the treatment of degenerative disc disease and spondylolisthesis other than either severe spondylolisthesis (grades 3 and 4) at L5-S1 or degenerative spondylolisthesis with objective evidence of neurologic impairment. These pedicle screw systems must comply with the following special controls: (i) The design characteristics of the device, including engineering schematics, must ensure that the geometry and material composition are consistent with the intended use. (ii) Non-clinical performance testing must demonstrate the mechanical function and durability of the implant. (iii) Device components must be demonstrated to be biocompatible. (iv) Validation testing must demonstrate the cleanliness and sterility of, or the ability to clean and sterilize, the device components and device-specific instruments. (v) Labeling must include the following: (A) A clear description of the technological features of the device including identification of device materials and the principles of device operation; (B) Intended use and indications for use, including levels of fixation; (C) Identification of magnetic resonance (MR) compatibility status; (D) Cleaning and sterilization instructions for devices and instruments that are provided non-sterile to the end user; and (E) Detailed instructions of each surgical step, including device removal. (3) Class II (special controls), when a semi-rigid system is intended to provide immobilization and stabilization of spinal segments in the thoracic, lumbar, and sacral spine as an adjunct to fusion for any indication. In addition to complying with the special controls in paragraphs (b)(2)(i) through (v) of this section, these pedicle screw systems must comply with the following special controls: (i) Demonstration that clinical performance characteristics of the device support the intended use of the product, including assessment of fusion compared to a clinically acceptable fusion rate. (ii) Semi-rigid systems marketed prior to the effective date of this reclassification must submit an amendment to their previously cleared premarket notification (510(k)) demonstrating compliance with the special controls in paragraphs (b)(2)(i) through (v) and paragraph (b)(3)(i) of this section.

Predicate Devices

• Rexious Spinal Fixation System (K111362)
• Globus Medical Inc. - CoCr rods (K100788)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

December 8, 2017

Huvexel Co., Ltd. % Mr. Milan George Senior Director Dio Medical Corporation 8770 W Bryn Mawr Avenue, Suite 1250 Chicago, Illinois 60631

Re: K173131

Trade/Device Name: Rexious Spinal Fixation System Regulation Number: 21 CFR 888.3070 Regulation Name: Thoracolumbosacral pedicle screw system Regulatory Class: Class II Product Code: NKB Dated: November 9, 2017 Received: November 13, 2017

Dear Mr. George:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820);

{1}------------------------------------------------

### Page 2 - Mr. Milan George

and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

# Ronald P. Jean -S for

Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

## Indications for Use

510(k) Number (if known) K173131

Device Name Rexious Spinal Fixation System

#### Indications for Use (Describe)

The Rexious Spinal Fixation System is intended to provide immobilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of the following acute and chronic instabilities or deformities of the thoracic, lumbar, and sacral spine: degenerative disc disease; spondylolisthesis; fracture; dislocation; scoliosis; kyphosis; spinal tumor; and failed previous fusion (pseudarthrosis).

Type of Use (Select one or both, as applicable)

X Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Druq Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

K173131

Page 1 of 2

# 510(k) SUMMARY

# HUVEXEL Co., Ltd's CoCr Rods & Additional Implants

| Sponsor: | Manufacturer | HUVEXEL Co., Ltd.<br>101-105 Megacenter, SK Technopark<br>124 Sagimakgol-ro, Jungwon-gu Seongnam-si<br>Gyeonggi-do, South Korea |
|------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|
| | Official Contact | Milan George |
| | Phone: | 267-737-9496 x102 |
| | Fax: | 847-795-1079 |
| | Date: | November 9, 2017 |
| Device Name: | Rexious Spinal Fixation System | |
| Common Name: | Pedicle Screw Spinal Fixation System | |
| Classification Name: | Thoracolumbosacral Pedicle Screw System | |
| Classification<br>Number: | 21 CFR 888.3070 | |
| Product<br>Code/Classification: | NKB, class II | |
| Description: | The Rexious Spinal Fixation System is a top-loading multiple component,<br>posterior spinal fixation system which consists fixation system which<br>consists of pedicle screws, rods, set screws, connectors, and transverse<br>(cross) linking mechanisms. | |
| | The Rexious Spinal Fixation System will allow surgeons to build a spinal<br>implant construct to stabilize and promote spinal fusion. The Rexious<br>implant components are supplied non-sterile, single use and fabricated<br>from titanium or titanium alloy (Ti-6Al-4V ELI) as specified in ASTM F67,<br>F136, and F1295 and from Cobalt-Chromium-Molybdenum (CoCr) as<br>specified in ASTM F1537. Various sizes of these implants are available. | |
| Device Modification &<br>Technological<br>Characteristics: | The purpose of this 510(k) submission is to introduce additional lengths of<br>rods, additional material for rods, additional screw sizes, and additional<br>transverse connector sizes. The modified system has the same intended<br>use and fundamental scientific technology as the previously-cleared<br>system. | |
| Intended Use: | The Rexious Spinal Fixation System is intended to provide<br>immobilization and stabilization of spinal segments in skeletally mature<br>patients as an adjunct to fusion in the treatment of the following acute<br>and chronic instabilities or deformities of the thoracic, lumbar, and<br>sacral spine: degenerative disc disease; spondylolisthesis; fracture;<br>dislocation; scoliosis; kyphosis; spinal tumor; and failed previous fusion<br>(pseudarthrosis). | |
| Performance Data: | The addition of components to the system did not introduce a new worst<br>case construct as evaluated based on an engineering analysis. Static and<br>Dynamic compression bend tests per ASTM F1717 were also performed. | |
| Predicate Device: | Primary predicate: Rexious Spinal Fixation System (K111362)<br>Additional predicate: Globus Medical Inc. - CoCr rods (K100788) | |
| Performance and SE<br>Determination: | The CoCr rods and additional Rexious implants have been demonstrated<br>to be substantially equivalent to the predicate system(s) with respect to<br>technical characteristics, performance, and intended use. The information<br>provided within this premarket notification supports substantial<br>equivalence of the subject device to the predicate device(s). | |

{4}------------------------------------------------